Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.
Also called NCT05700097
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 240 participants
- Sponsor
- Registry
-
NCT05700097
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT05700097. Randomized; quadruple masking; primary purpose treatment. Start 2022-09-30 (actual); primary completion 2023-09-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Dengzhanxixin Injection
- Intervention (Drug)
- Placebo injection
- Lead sponsor
- Beijing Tiantan Hospital
Record details
- Record id
cardio:ct-nct05700097- Content hash
782c41b385fa6be8dad71a1d78668f6bd11843f9f509893326a87aaf32570ff6